Facebook Twitter LinkedIn Google Plus RSS

PTC completes $60 million financing round

By ,

PTC Therapeutics Inc., of South Plainfield, on Thursday announced the completion of a $60 million round of financing, led by Brookside Capital Partners Fund L.P.

According to an announcement from PTC, proceeds from the financing will support continued development of Ataluren, a treatment for patients with muscular dystrophy and cystic fibrosis. The drug is in phase 3 trials.

You May Have Missed...

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy